Effect of recombinant interferon alfa-2b on cytokine production activity of immune system cells in children with COVID-19

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2022-01-01 DOI:10.20953/1729-9225-2022-3-26-34

G. Martynova, A. Savchenko, M. Stroganova, Ya. A. Bogvilene, L. A. Ikkes, V. Belenyuk, E.O. Shavrina

{"title":"Effect of recombinant interferon alfa-2b on cytokine production activity of immune system cells in children with COVID-19","authors":"G. Martynova, A. Savchenko, M. Stroganova, Ya. A. Bogvilene, L. A. Ikkes, V. Belenyuk, E.O. Shavrina","doi":"10.20953/1729-9225-2022-3-26-34","DOIUrl":null,"url":null,"abstract":"The clinical efficacy of recombinant IFN-α2b in therapy for COVID-19 in children is the basis for studying the parameters of the cytokine production activity of immune system cells and will allow to optimize antiviral therapy regimens. Objective. To study the effect of recombinant IFN-α2b on serum IFN-α and IFN-γ concentrations and their synthesis by immune system cells in children with COVID-19. Materials and methods. Peripheral blood samples from 100 patients aged 1 to 17 years (1–7 years – 50 people, 8–17 years – 50 people) with a moderate course of COVID-19 were examined. Patients in the study group received recombinant IFN-α2b as Вклюpart of complex therapy. Patients in the comparison group received antiviral therapy with Arbidol®. Multiplex analysis was used to determine serum IFN-α and IFN-γ concentrations and the level of their synthesis by immune system cells. The enzyme-linked immunosorbent assay (ELISA) was used to determine serum concentrations of antibodies to IFN-α. Results. Combination therapy with recombinant IFN-α2b in children of both age groups led to an increase in serum IFN-α concentrations compared to baseline values prior to treatment, in children in the control group and patients with COVID-19 after treatment with Arbidol. There were no significant changes in serum IFN-α and IFN-γ concentrations and their synthesis in intact and PHA-stimulated cells in children of both age groups during treatment with Arbidol. Serum concentrations of antibodies to IFN-α during treatment with recombinant IFN-α2b did not depend on the age of children and remained within the reference range. Conclusion. A significant increase in serum IFN-α concentrations and restoration of its synthesis level induced by PHA to reference values indicate that the use of recombinant interferon medications with their antiviral and immunomodulatory effects should become an integral part of COVID-19 therapy. Key words: children, COVID-19, recombinant interferon IFN-α2b, serum IFN-α concentrations, IFN-α synthesis levels","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2022-3-26-34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The clinical efficacy of recombinant IFN-α2b in therapy for COVID-19 in children is the basis for studying the parameters of the cytokine production activity of immune system cells and will allow to optimize antiviral therapy regimens. Objective. To study the effect of recombinant IFN-α2b on serum IFN-α and IFN-γ concentrations and their synthesis by immune system cells in children with COVID-19. Materials and methods. Peripheral blood samples from 100 patients aged 1 to 17 years (1–7 years – 50 people, 8–17 years – 50 people) with a moderate course of COVID-19 were examined. Patients in the study group received recombinant IFN-α2b as Вклюpart of complex therapy. Patients in the comparison group received antiviral therapy with Arbidol®. Multiplex analysis was used to determine serum IFN-α and IFN-γ concentrations and the level of their synthesis by immune system cells. The enzyme-linked immunosorbent assay (ELISA) was used to determine serum concentrations of antibodies to IFN-α. Results. Combination therapy with recombinant IFN-α2b in children of both age groups led to an increase in serum IFN-α concentrations compared to baseline values prior to treatment, in children in the control group and patients with COVID-19 after treatment with Arbidol. There were no significant changes in serum IFN-α and IFN-γ concentrations and their synthesis in intact and PHA-stimulated cells in children of both age groups during treatment with Arbidol. Serum concentrations of antibodies to IFN-α during treatment with recombinant IFN-α2b did not depend on the age of children and remained within the reference range. Conclusion. A significant increase in serum IFN-α concentrations and restoration of its synthesis level induced by PHA to reference values indicate that the use of recombinant interferon medications with their antiviral and immunomodulatory effects should become an integral part of COVID-19 therapy. Key words: children, COVID-19, recombinant interferon IFN-α2b, serum IFN-α concentrations, IFN-α synthesis levels

查看原文本刊更多论文

重组干扰素α -2b对COVID-19患儿免疫系统细胞因子产生活性的影响

重组IFN-α2b治疗儿童COVID-19的临床疗效是研究免疫系统细胞细胞因子产生活性参数的基础，为优化抗病毒治疗方案提供依据。目标。目的研究重组IFN-α2b对COVID-19患儿血清IFN-α和IFN-γ浓度及免疫系统细胞合成的影响。材料和方法。对100例1 - 17岁(1 - 7岁50例，8-17岁50例)中度病程COVID-19患者的外周血样本进行了检测。研究组患者接受重组IFN-α2b Вклюpart复合治疗。对照组患者接受阿比多尔抗病毒治疗。采用多重分析法测定血清IFN-α和IFN-γ浓度及免疫系统细胞合成水平。采用酶联免疫吸附试验(ELISA)测定血清中IFN-α抗体的浓度。结果。两组儿童联合应用重组IFN-α2b治疗，对照组儿童和COVID-19患者在阿比多尔治疗后血清IFN-α浓度均高于治疗前的基线值。阿比多尔治疗期间，两组儿童血清IFN-α和IFN-γ浓度及其在完整细胞和pha刺激细胞中的合成均无显著变化。重组IFN-α2b治疗期间血清IFN-α抗体浓度与儿童年龄无关，且保持在参考范围内。结论。PHA诱导的血清IFN-α浓度显著升高，IFN-α合成水平恢复到参考值，表明具有抗病毒和免疫调节作用的重组干扰素药物应成为COVID-19治疗的重要组成部分。关键词:儿童，COVID-19，重组干扰素IFN-α2b，血清IFN-α浓度，IFN-α合成水平

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.